Your browser doesn't support javascript.
loading
Net Remission Rates with Biologic Treatment in Crohn's Disease: A Reappraisal of the Clinical Trial Data.
Kayal, Maia; Ungaro, Ryan C; Bader, Geoffrey; Colombel, Jean-Frederic; Sandborn, William J; Stalgis, Carlos.
Afiliação
  • Kayal M; Division of Grastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York. Electronic address: Maia.Kayal@mountsinai.org.
  • Ungaro RC; Division of Grastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York.
  • Bader G; Division of Gastroenterology, Brooke Army Medical Center, San Antonio, Texas.
  • Colombel JF; Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York.
  • Sandborn WJ; Division of Gastroenterology, University of California San Diego, San Diego, California.
  • Stalgis C; Ortelius Insight, Los Angeles, California.
Clin Gastroenterol Hepatol ; 21(5): 1348-1350, 2023 05.
Article em En | MEDLINE | ID: mdl-35245701
ABSTRACT
Biologic therapies have greatly advanced the medical care of patients with Crohn's disease (CD); however, up to 50% of patients have no response and up to 80% fail to achieve remission.1-4 One way to investigate this treatment gap in CD is to look at the "net" remission rates in clinical trials defined as the actual percentage of patients enrolled during induction who are in remission at the end of maintenance. Indeed, most of the seminal clinical trials in CD used a "responder" methodology, where only patients who responded during induction were rerandomized to maintenance.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Produtos Biológicos / Doença de Crohn Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Produtos Biológicos / Doença de Crohn Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article